

## **Does Histopathology Predict the Outcome of Fatty Liver Resection and Transplantation?**

**Ashraf Mohammad El-Badry MD<sup>1,2,\*</sup>, Emad Ali Ahmed MD<sup>2,3</sup>, Federico Mocchegiani MD<sup>3</sup>**

<sup>1</sup>Surgical Oncology, <sup>2</sup>Hepato-Pancreatobiliary Surgery Units, Department of Surgery, Sohag University Hospital, Faculty of Medicine, Sohag University, Sohag, Egypt, and <sup>3</sup>Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy

\* Corresponding author: Ashraf Mohammad El-Badry MD, Department of Surgery, Sohag University Hospital, University Street, 82524 Sohag, Egypt. E-mail: [ashraf.elbadry@med.sohag.edu.eg](mailto:ashraf.elbadry@med.sohag.edu.eg)

### **Abstract:**

Hepatic steatosis is widely considered as substantial risk factor for postoperative complications after major hepatectomy and liver transplantation. Nonetheless, studies have been inconsistent regarding the extent of steatosis pertinent to aggravation of liver injury. Furthermore, a significant number of studies failed to show any link between hepatic steatosis and worse postoperative outcome. The confusion is further nourished by the conflicting observations on the impact of steatosis on survival rates following colorectal liver metastasectomy and also on the regenerative capacity of the fatty liver. We assume that these controversies are related to inconsistent evaluation of hepatic steatosis even among expert pathologists. In this mini-review, we will underline the limitations of the histo-pathological assessment of hepatic steatosis. The emerging role of chemical composition of hepatic lipids, particularly the balance between  $\Omega$ -3 and  $\Omega$ -6 fatty acids, in liver protection/injury will be highlighted. Finally, the conflicting studies on the impact of various histo-pathological grades and types of hepatic steatosis on the clinical outcome after liver resection and transplantation will be analyzed.

**Keywords:** Steatosis, microsteatosis, macrosteatosis, liver resection, transplantation

### **1 Introduction:**

Patients with hepatic steatosis are commonly assumed to be more vulnerable to postoperative complications after liver resection and transplantation [1]. The current literature is abundant in correlating hepatic steatosis with postoperative complications and mortality after resectional and transplant surgery of the liver [2-7], however several studies failed to show a negative impact of steatosis on the clinical outcome [8, 9]. In the

setting of liver regeneration, steatosis is thought to jeopardize restoration of liver volume after partial hepatectomy [1]. Recently, impairment of fatty liver regeneration in mice was shown to be related to inhibition of growth arrest and DAN damage-inducible protein (GADD34) and that overexpression of the same protein ameliorates liver regeneration [10]. Clinically, obese patients with liver steatosis show weak hepatic regenerative



response to major liver resection as reflected by reduced liver volumetric gain compared with matched non-obese controls [11]. In sharp contrast, liver regeneration is not significantly affected in high fat diet-induced simple steatosis in rats, compared with the lean animals [12]. Furthermore, a mild degree of diet-induced simple steatosis was demonstrated to enhance liver regeneration in mice [13]. This pro-proliferative influence was associated with increased expression of fatty acid transport protein and hepatocyte growth factor [13].

The ambiguous definition of liver steatosis in many studies and variability in the diagnostic methods appear, in our view, to be seriously affecting the validity of such studies. Steatosis of the liver is characterized quantitatively in relation to the percentage of hepatocytes containing lipid droplets into mild (<30%), moderate (30-60%) and severe (>60%) grades [14]. Qualitatively, hepatic steatosis is separated into two entities (micro- and macrosteatosis) according to the size of lipid droplets and the location of nucleus in the hepatocyte cytoplasm [14]. This approach continues to be applied despite several pitfalls during the histological workup and the inconsistency among pathologists.

## **2 Histopathology, Imaging and Chemistry of Hepatic Lipids: Which Is Critical for the outcome of Liver Resection and Transplantation?**

Assessment of the grade and type and the distinction between simple steatosis and non-alcoholic steatohepatitis traditionally relies on microscopic evaluation by pathologists [14]. This subjective histopathological evaluation has gained clinical grounds since 1989, when pathologists from Pittsburgh described two cases of primary non-function due to high rate of macrosteatosis in many hepatocytes [15]. On this basis, several studies demonstrated that liver steatosis is a substantial risk factor for poor outcome after major hepatectomy [16, 17] and orthotopic

liver transplantation (OLT) [18-21], while others failed to document negative effect [22-26]. The microscopic diagnosis of hepatic steatosis encompasses a number of pitfalls, as discussed below, which may significantly influence the interpretation. There is emerging evidence that modern imaging techniques may provide more precise quantification of hepatic fat content [27]. Moreover, the chemical composition of liver fat is evolving as key-player in liver ischemia/reperfusion injury [28].

### ***2.1 The size number of biopsy samples***

The importance of the biopsy size is frequently underestimated. An adequate biopsy sample should not be less than 1.6 cm length and 1.2-1.8 mm width and comprises about 10 portal tracts [29]. Of note, this "adequate" tissue sample will approximately be 1:50.000 of the total volume of the liver, which will never be enough to mirror the status of the parenchyma of the whole organ [29]. In a study reported by Vuppalanchi et al [30], three cores of liver biopsies were obtained percutaneously from each of 50 patients with suspected liver steatosis. The evaluation by blinded pathologist led to a diagnosis of steatosis that was significantly higher when three samples were assessed compared with the assessment of only two samples [30].

### ***2.2 Tissue fixatives and staining methods***

Different fixatives can alter the diagnosis of hepatic steatosis via induction of fusions or disintegration of LDs. Cold methanol removes most cellular phospholipids and enhances fusion of LDs. Acetone fixation extracts total cellular lipids with subsequent collapse of LDs [35]. Visualization of LDs is noticeably prejudiced by the staining method. Fukumoto et al [32] noticed that LDs labeled by Nile red display different shape compared with those stained by Sudan III, and oil red O. The authors found that ethanol and isopropanol used for Sudan III and oil red O staining, respectively, and glycerol used for mounting, cause fusion of adjacent LDs [32].



Immunofluorescence labeling for adipose differentiation-related protein (ADRP), a LD marker, was dislocated to the rim of large LDs which have formed as a result of fusion [32].

### ***2.3 The inter-observer agreement:***

High inter-observer disagreement was documented even among expert pathologists regarding both the quantitative and qualitative assessment of steatosis as well as steatohepatitis [33]. The assessment of 46 high-resolution images of H&E stained liver sections by 4 renowned pathologists disclosed poor concordance regarding the degree of total, macro- and microsteatosis. Lack of agreement was observed also with the semiquantitative evaluation; for instance, the diagnosis of marked steatosis ( $\geq 30\%$ ) varied from 22% to 46%. Pathologists were asked to interpret 4 features of steatohepatitis (lobular and portal inflammation, hepatocyte ballooning and Mallory's hyaline) as absent or present and to provide an overall diagnosis of steatohepatitis. A disagreement among pathologists was evident with regard to the assessment of all parameters as well as the final diagnosis of steatohepatitis [33]. These results possibly explain the inconsistency among published studies on the relevance of liver steatosis to liver surgery and transplantation.

### ***2.4 Imaging techniques for assessment of liver steatosis:***

Ultrasound examination of the liver is the most commonly used modality for assessment of steatosis [34]. Despite the ability of conventional cross-sectional imaging such as computed tomography (CT) and magnetic resonance imaging (MRI) to provide more reliable diagnosis, both techniques failed to show significant agreement with the conventional histopathological evaluation [35]. In a study on 161 live liver donors who underwent liver steatosis assessment by ultrasonography, computed tomography, proton magnetic resonance spectroscopy and dual gradient echo MRI, the later outperformed

all other modalities [27]. However, this study provided no data on the relation between liver steatosis quantified by each method and the clinical outcome after live donor hepatectomy [27]. To overcome the uncertainty of histopathologic assessment, chemical lipid assay was applied as more reliable reference for the amount of intrahepatic fat in murine liver steatosis models [36, 37]. Significant agreement was observed between MRI estimation of the magnitude of hepatic fatty infiltration compared with chemical lipid assay [36, 37]. Moreover, two different studies showed that patients with liver content  $\geq 5\%$  [38] and  $> 10\%$  (36) assessed by MRI exhibited higher grades of surgical complications, including organ failure and sepsis, compared with those who have  $< 5\%$  and  $< 10\%$ , respectively [36, 38].

### ***2.5 The Role of chemical composition of hepatic lipids in hepatocellular protection/injury:***

The histological evaluation of hepatic steatosis as a predictor of the clinical outcome ignores the chemical lipid composition [28]. Dietary models of hepatic steatosis in rats with similar total triglycerides, but different composition of fatty acids (FAs), show that increased saturated FAs is associated with enhanced liver injury and markers of endoplasmic reticulum stress such as X-box binding protein-1 mRNA splicing and glucose-regulated protein 78 expression [39]. Noteworthy, the rise of saturated FAs was associated with reduced liver regeneration in response to partial hepatectomy and increased lipopolysaccharide-induced liver damage [39].

In a rodent model of hepatic macrosteatosis, more pronounced hepatocellular injury after ischemic stress was shown in comparison with lean animals. The mechanism of injury was mostly related to reduced sinusoidal perfusion which has been successfully managed by preconditioning with dietary  $\Omega$ -3 FAs [40]. In humans, three live liver donors with moderate steatosis were



treated with oral  $\Omega$ -3 FAs capsules prior to right hemi-hepatectomy. This approach resulted in remarkable reduction of steatosis grade and the extent of macrosteatosis within one month [41].

Supplementation of ob/ob mice with  $\Omega$ -3 FAs decreased hepatic levels of arachidonic acid before ischemia, diminished hepatic TXA<sub>2</sub> production after reperfusion. As a result, significant amelioration of sinusoidal perfusion and protection against hepatocellular damage were conferred. Similar protection was observed by the use of selective TXA<sub>2</sub> receptor blockage without alteration of the histological pattern of intrahepatic lipids (28). In humans, circulating levels of TXB<sub>2</sub>, a metabolite of TXA<sub>2</sub>, were remarkably increased during hepatic resection. Intravenous administration of TXA<sub>2</sub> synthase inhibitor intraoperatively reduced plasma TXB<sub>2</sub> and concomitantly blunted serum transaminase levels [42].

### 3 Liver Steatosis and the Clinical Outcome of Liver Resection:

Many studies on the impact of steatosis on the outcome of liver surgery have been published over the last two decades. In the light of the aforementioned pitfalls of the microscopic evaluation of steatosis, clinical data on the impact of steatosis on the clinical outcome after liver resection are conflicting and often difficult to be convincingly interpreted.

In a retrospective analysis of a large series of liver resections involving 325 steatotic versus 997 non-steatotic patients, uni- and multivariate analyses showed no negative effect of steatosis on postoperative complications or patient survival. This result might be influenced by inclusion of minor liver resections [19]. Kooby et al [43] compared 325 patients with fatty liver with 160 lean controls regarding the clinical outcome after hepatic resection for liver neoplasms. The authors reported that marked steatosis was independent predictor of postoperative complications but

not for 60-day mortality [43]. Two studies demonstrated that marked steatosis ( $\geq 30\%$ ) is an independent risk factor for post-hepatectomy complications. However, data on the postoperative mortality were inconsistent [16, 17]. In a case-matched control study, steatosis of any grade significantly predicted postoperative complications. Cholestasis was significant risk factor for mortality after resection of the steatotic patients [6]. A retrospective study on 194 steatotic patients who underwent liver resection for colorectal liver metastasis (CRLM), morbidity, including infective complications, and admissions to intensive care unit correlated with increasing grades of steatosis [7]. A meta-analysis of 1000 patients enrolled in 4 observational studies showed that steatotic patients had twofold increase in postoperative morbidity and that the severe form carries nearly threefold higher risk of post-hepatectomy death [4]. In a study on the clinical outcome after major hepatectomy with portal vein resection, hepatic steatosis was associated with remarkably higher rate of postoperative mortality [3]. However, in 2715 patients, among them 927 were steatotics, Hamady et al [59] documented that patients with liver steatosis have substantially higher risk of postoperative liver failure and local recurrence [44]. Contrarily, no statistically significant increase in postoperative complications could be found following major hepatectomy in obese-steatotic patients compared with matched non obese- non steatotic controls, despite documented impairment in postoperative volumetric liver gain in the former group [11]. These data are further supported by a report on liver metastasectomy for CRLM in 513 non steatotic versus 421 patients with different degrees of steatosis. No significant difference in terms of postoperative morbidity, mortality or tumor recurrence could be documented between steatotic and non steatotic patients even after case-control matching [45]. In the same line, steatohepatitis but not simple steatosis was reported to increase overall and hepatectomy-related surgical complications [8, 9]. Analysis of data from LiverMetSurvey database showed



that liver steatosis that develops after neoadjuvant chemotherapy exerted no negative influence of peri-operative mortality, 5- year overall and cancer specific survival after first liver resection for CRLM [46]. Steatotic patients who were registered in the LiverMetSurvey database and underwent first liver resection of CRLM without prior chemotherapy similar 90-day perioperative mortality to those with normal liver parenchyma. In comparison with normal parenchymal background, steatosis was surprisingly associated with significantly improved overall and cancer specific survival [47]. The disagreement extends to studies on live donors for living donor liver transplantation (LDLT). For instance, postoperative transaminase and bilirubin levels as well as morbidity rates were not significantly different between donors with mild (5-30%) versus no macrosteatosis [25]. Nevertheless, in another study on LDLT, mild macrosteatosis (up to 20%) was documented as independent risk factor for postoperative hyperbilirubinemia [48]. These conflicting results could be related to inconsistent evaluation of steatosis in liver sections.

#### **4 Graft Steatosis and Survival after Liver Transplantation:**

The current shortage of high quality grafts has led to the increasing use of so-called “extended criteria” grafts, among which steatotic livers are the most common. Increasing degrees of steatosis, particularly the macrovesicular form, is thought to have detrimental effect on graft and patient survival after orthotopic liver transplantation (OLT) [49]. The vast majority of European transplant centers reject implantation of grafts with severe steatosis for any patient [5]. However, the results from studies reporting on the effect of hepatic steatosis on graft and recipient survival are not consistent.

Analysis of the outcome of OLT in patients with variable grades of steatosis showed significant correlation between

enhanced hepatocellular injury and increased degrees of steatosis. Severe renal failure requiring hemofiltration /hemodialysis occurred more frequently in recipients of severely steatotic grafts. Severe steatosis was associated with significant increase of early (90 days) mortality [50]. In a case-control matched study, morbidity and mortality after OLT were studied in 57 recipients of donor livers with up to 30% steatosis. The control group included 59 patients who received grafts without fatty infiltration [13]. Median transaminase value at the second postoperative day was significantly higher in the fatty liver group. Surprisingly, mild steatosis was associated with significant decline in the 4-month graft survival and in 2-year patient survival. In multivariate analysis, steatosis was independent risk factor for graft loss [18]. The clinical outcome of OLT in 115 patients who were categorized according to the grade of steatosis into four groups was prospectively analyzed [51]. There was no significant differences among all groups with regard to the demographic data, donor age, weight and body mass index, etiology of liver disease, indications of OLT and MELD (Model for End Stage Liver Disease) score [51]. Graft survival at 1-year was significantly lower with severe compared with absent and even mild and moderate steatosis groups [51]. In the same line, severe graft steatosis exerted a significant influence on one year patient survival compared with non-and mildly steatotic organs [58]. No negative effect on graft or patient survival could be documented in hepatitis C virus positive recipients; however, the study may be limited by the small number of patients in each subgroup [51]. Another study showed that graft survival is significantly lowered with increasing grades of steatosis at one month but not at 3-months or one year [16]. Of note, graft loss in presence of steatosis was significantly influenced by increased rates of recurrent hepatitis C and the older age [21].

Contrarily, liver grafts with more than 50% steatosis exhibited adequate initial graft function and no compromise to early (30-day) patient survival [36]. It should be noted that

prolonged ischemia was avoided in the fatty organs and non-among recipients of fatty liver suffered from other risk factors such as emergency or re-transplantation [52]. In another study, the outcome of the use of severely steatotic grafts for OLT was analyzed [5]. Despite the higher rate of primary graft dysfunction, renal failure, prolonged intensive care unit and hospital stay with severe steatosis, 60-day mortality and 3-year patient survival were not negatively affected [5]. In line with these data, a study on the cumulative graft survival in patients who received grafts with mild compared with moderate and severe steatosis showed no significant difference despite impaired graft function postoperatively [26]. In 2 groups of mild and moderate fatty graft recipients who were matched for age, gender, MELD score and cold ischemic time, moderate steatosis was not associated with any negative impact on patient survival at 1 year [53]. Nineteen recipients of moderately macrosteatotic grafts were compared with 195 matched controls. Despite increased postoperative complication rates steatotic graft recipients, short and long-term survival of the grafts and patients were similar [54]. Recently, Wong et al investigated the results of implantation of deceased donor grafts with severe forms of macrosteatosis  $> 60\%$  versus  $\leq 60$  in 19 and 354 patients, respectively. Graft and patient survival rates were almost similar in both groups [55]. A Japanese group demonstrated that implantation of organs with mild and moderate steatosis results in comparable graft and patient survival with normal grafts while severe steatosis led to worse outcome in LDLT. Noteworthy, histological assessment and computed tomography were used for evaluation of steatosis [20]. In another series of LDLT (20), steatosis grades of the grafts biopsy ranged from mild (1- 20%) to moderate (21-50%). Steatotic donors had significantly higher body mass index. Although the peak transaminase levels were significantly higher with steatosis, both groups showed comparable 1-year graft survival [24].

In the setting of OLT for hepatitis C virus positive recipients, patient survival at 5 years was significantly decreased with increasing degree of steatosis. Graft survival at 3 years showed also significant inverse relation with the increasing degree of steatosis. Aside from gender, analysis of marginal donor variables showed no significant difference among steatotic and non steatotic donors [56]. In contrast, another group observed no negative influence when steatotic grafts were transplanted to patient's positive for hepatitis C virus [57]. In patients requiring re-transplantation, severe microsteatosis significantly lowered the 1-year graft survival [58]. Likewise, at post-transplant day 7, initial poor graft function was significantly related to presence of microvesicular steatosis [59]. High grade ( $>30\%$ ) macrosteatosis was also reported to induce remarkable shortening of both graft and patient survival [19]. Furthermore, in 311 consecutive OLTs, 5 among 8 patients with graft macrosteatosis of  $\geq 25\%$ , died within the first year. However, the effect of macrosteatosis on graft survival was not significant [60].

## 5 Conclusions and Perspectives:

The influence of intrahepatic lipids on the clinical outcome after fatty liver resection and transplantation is currently viewed from the side of shape and size of LDs and lipid quantity as assessed by imaging studies. However, the recent evidence on potential role for lipid metabolites, which are derived from the hepatic lipid content, warrants further consideration in future studies.

## Reference:

- [1] Forbes SJ, Newsome PN. Liver regeneration - mechanisms and models to clinical application. *Nat Rev Gastroenterol Hepatol*. 2016 Aug;13(8):473–85.
- [2] Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in



liver surgery. *Ann Surg.* 2007 Jan;245(1):20–30.

[3] Bachellier P, Rosso E, Pessaux P, Oussoultzoglou E, Nobili C, Panaro F, et al. Risk factors for liver failure and mortality after hepatectomy associated with portal vein resection. *Ann Surg.* 2011 Jan;253(1):173–9.

[4] de Meijer VE, Kalish BT, Puder M, Ijzermans JNM. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. *Br J Surg.* 2010 Sep;97(9):1331–9.

[5] McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien P-A. Use of severely steatotic grafts in liver transplantation: a matched case-control study. *Ann Surg.* 2007 Dec;246(6):940-946-948.

[6] McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien P-A. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. *Ann Surg.* 2007 Jun;245(6):923–30.

[7] Gomez D, Malik HZ, Bonney GK, Wong V, Toogood GJ, Lodge JPA, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. *Br J Surg.* 2007 Nov;94(11):1395–402.

[8] Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. *Hepatology* Baltim Md. 2012 Dec;56(6):2221–30.

[9] Wiggans MG, Lordan JT, Shahtahmassebi G, Aroori S, Bowles MJ, Stell DA. The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications. *HPB Surg World J Hepatic Pancreat Biliary Surg.* 2014;2014:586159.

[10] Inaba Y, Furutani T, Kimura K, Watanabe H, Haga S, Kido Y, et al. Growth arrest and DNA damage-inducible 34 regulates liver regeneration in hepatic steatosis in mice. *Hepatology* Baltim Md. 2015 Apr;61(4):1343–56.

[11] Truant S, Bouras AF, Petrovai G, Buob D, Ernst O, Boleslawski E, et al. Volumetric gain of the liver after major hepatectomy in obese patients: a case-matched study in 84 patients. *Ann Surg.* 2013 Nov;258(5):696-702-704.

[12] Garnol T, Kučera O, Staňková P, Lotková H, Červinková Z. Does Simple Steatosis Affect Liver Regeneration after Partial Hepatectomy in Rats? *Acta Medica (Hradec Kralove).* 2016;59(2):35–42.

[13] Sydor S, Gu Y, Schlattjan M, Bechmann LP, Rauhen U, Best J, et al. Steatosis does not impair liver regeneration after partial hepatectomy. *Lab Investig J Tech Methods Pathol.* 2013 Jan;93(1):20–30.

[14] El-Badry AM, Graf R, Clavien P-A. Omega 3 - Omega 6: What is right for the liver? *J Hepatology.* 2007 Nov;47(5):718–25.

[15] Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. *Transplantation.* 1989 May;47(5):903–5.

[16] Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. *J Gastrointest Surg Off J Soc Surg Aliment Tract.* 1998 Jun;2(3):292–8.

[17] Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. *J Am Coll Surg.* 2000 Jul;191(1):38–46.



- [18] Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. *Transplantation*. 1996 Nov 15;62(9):1246–51.
- [19] Ureña MA, Ruiz-Delgado FC, González EM, Seguro CL, Romero CJ, García IG, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. *Transplant Proc*. 1998 Nov;30(7):3288–91.
- [20] Hayashi M, Fujii K, Kiuchi T, Uryuhara K, Kasahara M, Takatsuki M, et al. Effects of fatty infiltration of the graft on the outcome of living-related liver transplantation. *Transplant Proc*. 1999 Mar;31(1–2):403.
- [21] Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2003 May;9(5):500–5.
- [22] Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, et al. Use of livers with microvesicular fat safely expands the donor pool. *Transplantation*. 1997 Jul 27;64(2):248–51.
- [23] Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg*. 2002 Oct;236(4):397-406-407.
- [24] Soejima Y, Shimada M, Suehiro T, Kishikawa K, Yoshizumi T, Hashimoto K, et al. Use of steatotic graft in living-donor liver transplantation. *Transplantation*. 2003 Jul 27;76(2):344–8.
- [25] Cho JY, Suh K-S, Kwon CH, Yi N-J, Lee KU. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. *Surgery*. 2006 Apr;139(4):508–15.
- [26] Angele MK, Rentsch M, Hartl WH, Wittmann B, Graeb C, Jauch KW, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. *Am J Surg*. 2008 Feb;195(2):214–20.
- [27] Lee SS, Park SH, Kim HJ, Kim SY, Kim M-Y, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. *J Hepatol*. 2010 Apr;52(4):579–85.
- [28] El-Badry AM, Jang J-H, Elsherbiny A, Contaldo C, Tian Y, Raptis DA, et al. Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A(2). *J Hepatol*. 2011 Dec;55(6):1291–9.
- [29] Nalbantoglu ILK, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. *World J Gastroenterol*. 2014 Jul 21;20(27):9026–37.
- [30] Vuppalanchi R, Unalp A, Van Natta ML, Cummings OW, Sandrasegaran KE, Hameed T, et al. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc*. 2009 Apr;7(4):481–6.
- [31] DiDonato D, Brasaemle DL. Fixation methods for the study of lipid droplets by immunofluorescence microscopy. *J Histochem Cytochem Off J Histochem Soc*. 2003 Jun;51(6):773–80.
- [32] Fukumoto S, Fujimoto T. Deformation of lipid droplets in fixed samples. *Histochem Cell Biol*. 2002 Nov;118(5):423–8.



- [33] El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. *Ann Surg.* 2009 Nov;250(5):691–7.
- [34] Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. *Ann Hepatol.* 2009;8 Suppl 1:S25-33.
- [35] Cho CS, Curran S, Schwartz LH, Kooby DA, Klimstra DS, Shia J, et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. *J Am Coll Surg.* 2008 Mar;206(3):480–8.
- [36] Raptis DA, Fischer MA, Graf R, Nanz D, Weber A, Moritz W, et al. MRI: the new reference standard in quantifying hepatic steatosis? *Gut.* 2012 Jan;61(1):117–27.
- [37] Leiber L-M, Boursier J, Michalak S, Roullier V, Fizanne L, Chaigneau J, et al. MRI versus histological methods for time course monitoring of steatosis amount in a murine model of NAFLD. *Diagn Interv Imaging.* 2015 Sep;96(9):915–22.
- [38] d'Assignies G, Fayard C, Leitao H, Alfaiate T, Tubach F, Dokmak S, et al. Liver steatosis assessed by preoperative MRI: An independent risk factor for severe complications after major hepatic resection. *Surgery.* 2016 Apr;159(4):1050–7.
- [39] Wang D, Wei Y, Pagliassotti MJ. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. *Endocrinology.* 2006 Feb;147(2):943–51.
- [40] El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien P-A. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. *Hepato Baltim Md.* 2007 Apr;45(4):855–63.
- [41] Clavien P-A, Oberkofler CE, Raptis DA, Lehmann K, Rickenbacher A, El-Badry AM. What is critical for liver surgery and partial liver transplantation: size or quality? *Hepato Baltim Md.* 2010 Aug;52(2):715–29.
- [42] Shirabe K, Takenaka K, Yamamoto K, Kitamura M, Itasaka H, Matsumata T, et al. The role of prostanoid in hepatic damage during hepatectomy. *Hepatogastroenterology.* 1996 Jun;43(9):596–601.
- [43] Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al. Impact of steatosis on perioperative outcome following hepatic resection. *J Gastrointest Surg Off J Soc Surg Aliment Tract.* 2003 Dec;7(8):1034–44.
- [44] Hamady ZZR, Rees M, Welsh FK, Toogood GJ, Prasad KR, John TK, et al. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. *Br J Surg.* 2013 May;100(6):820–6.
- [45] Ramos E, Torras J, Lladó L, Rafecas A, Serrano T, Lopez-Gordo S, et al. The influence of steatosis on the short- and long-term results of resection of liver metastases from colorectal carcinoma. *HPB.* 2016 Apr;18(4):389–96.
- [46] Parkin E, O'Reilly DA, Adam R, Kaiser GM, Laurent C, Elias D, et al. Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following preoperative chemotherapy. *Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol.* 2014 Nov;40(11):1436–44.
- [47] Parkin E, O'Reilly DA, Adam R, Kaiser GM, Laurent C, Elias D, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. *HPB.* 2013 Jun;15(6):463–72.

[48] Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. *Br J Surg*. 2009 Apr;96(4):437–44.

[49] Durand F, Renz JF, Alkofer B, Burra P, Clavien P-A, Porte RJ, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2008 Dec;14(12):1694–707.

[50] Perez-Daga JA, Santoyo J, Suárez MA, Fernández-Aguilar JA, Ramírez C, Rodríguez-Cañete A, et al. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. *Transplant Proc*. 2006 Oct;38(8):2468–70.

[51] Noujaim HM, de Ville de Goyet J, Montero EFS, Ribeiro CMF, Capellozzi VL, Crescentini F, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. *Transplantation*. 2009 Mar 27;87(6):919–25.

[52] Afonso RC, Saad WA, Parra OM, Leitão R, Ferraz-Neto BH. Impact of steatotic grafts on initial function and prognosis after liver transplantation. *Transplant Proc*. 2004 May;36(4):909–11.

[53] Gao F, Xu X, Ling Q, Wu J, Zhou L, Xie H-Y, et al. Efficacy and safety of moderately steatotic donor liver in transplantation. *Hepatobiliary Pancreat Dis Int HBPD INT*. 2009 Feb;8(1):29–33.

[54] Westerkamp AC, de Boer MT, van den Berg AP, Gouw ASH, Porte RJ. Similar outcome after transplantation of moderate macrovesicular steatotic and nonsteatotic livers when the cold ischemia time is kept very short. *Transpl Int Off J Eur Soc Organ Transplant*. 2015 Mar;28(3):319–29.

[55] Wong TCL, Fung JYY, Chok KSH, Cheung TT, Chan ACY, Sharr WW, et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2016 Feb;22(2):226–36.

[56] Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2009 Jan;15(1):37–48.

[57] Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. *Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc*. 2009 Jun;15(6):619–28.

[58] Yoong KF, Gunson BK, Neil DA, Mirza DF, Mayer AD, Buckels JA, et al. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. *Transplant Proc*. 1999 Mar;31(1–2):550–1.

[59] Cieślak B, Lewandowski Z, Urban M, Ziarkiewicz-Wróblewska B, Krawczyk M. Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters. *Transplant Proc*. 2009 Oct;41(8):2985–8.

[60] Zamboni F, Franchello A, David E, Rocca G, Ricchiuti A, Lavezzo B, et al. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. *Clin Transplant*. 2001 Feb;15(1):53–7.